Gefitinib

COMPOSITION:

Each film-coated tablet contains Gefitinib……………………….. 250 mg.

INDICATIONS

LuciGefi is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non- small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

Limitation of Use:

Safety and efficacy of LuciGefi have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.

DOSAGE AND USE:

Recommended dose is 250 mg orally, once daily with or without food.

STORAGE:

In a dry place and store at 20℃ to 25℃.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNINGS:

Keep medicine out of reach of Children. Do not administer LuciGefi during Pregnancy and Lactation.